Oral Adherence With Nerlynx® (Neratinib) Tablets: Conversation With an Expert, Part 1

Q: Why are there potential challenges with oral oncolytic adherence?

A: I think the basic one is a lack of knowl­edge on the part of the patient and some­times the provider, or whoever is educating the patient. Inadequate follow-up is another challenge. I know our practice is extremely busy, as are other practices, and it’s hard to even find a spot for some of these patients. The third challenge is that patients perceive oral therapy as being safer and less toxic, but they also don’t realize the impact on outcome from missing “just one dose.”